Skip to main content
Equibles

CITADEL ADVISORS LLC

Position in VRTX — Vertex Pharmaceuticals Inc / Ma

CIK 1423053 MIAMI, FL
Back to VRTX Full portfolio

Position in VRTX

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$151,510,128
-$42,101,793 QoQ
Shares Held
339,298
-20.6% QoQ
Ownership
0.134%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in VRTX Over Time

Shares Held

Position Value (USD)

Derivatives in VRTX

reported options exposure · as of Mar 31, 2026
CallValue
$100,069,614
CallShares
224,100
PutValue
$30,409,374
PutShares
68,100

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

CITADEL ADVISORS LLC holds $5,780,363,972 across 373 Biotechnology names. VRTX ranks #11 (2.6% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 INSM
INSMED Inc
 2,182,571 $356,894,009
2 ONC
BeOne Medicines Ltd.
 1,032,298 $306,561,536
3 BMRN
Biomarin Pharmaceutical Inc
 4,512,634 $254,918,694
4 JAZZ
Jazz Pharmaceuticals plc
 1,259,444 $238,097,887
5 MDGL
Madrigal Pharmaceuticals, Inc.
 453,843 $237,573,195
6 BBIO
BridgeBio Pharma, Inc.
 3,173,940 $235,696,783
7 TERN
Terns Pharmaceuticals, Inc.
 3,218,810 $169,695,662
8 PTGX
Protagonist Therapeutics, Inc
 1,551,900 $163,570,260

All Filings in VRTX

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $151,510,128 339,298
2026-03-31 $100,069,614 224,100
2026-03-31 $30,409,374 68,100
2025-12-31 $51,909,720 114,500
2025-12-31 $112,614,624 248,400
2025-12-31 $193,611,921 427,060
2025-09-30 $67,950,322 173,502
2025-09-30 $107,857,656 275,400
2025-09-30 $53,263,040 136,000
2025-06-30 $55,694,520 125,100
2025-06-30 $141,929,760 318,800
2025-06-30 $12,833,780 28,827
2025-03-31 $2,433,311 5,019
2025-03-31 $134,295,140 277,000
2025-03-31 $50,615,208 104,400
2024-12-31 $65,310,288 162,181
2024-12-31 $69,183,860 171,800
2024-12-31 $139,777,170 347,100
2024-09-30 $43,810,536 94,200
2024-09-30 $23,361,898 50,232
2024-09-30 $97,434,260 209,500
2024-06-30 $52,590,384 112,200
2024-06-30 $49,025,767 104,595
2024-06-30 $63,464,688 135,400
2024-03-31 $62,283,490 149,000
2024-03-31 $34,265,533 81,973
2024-03-31 $61,113,062 146,200
2023-12-31 $55,296,351 135,900
2023-12-31 $76,291,875 187,500
2023-12-31 $132,922,824 326,680
2023-09-30 $48,961,792 140,800
2023-09-30 $47,709,928 137,200
2023-09-30 $9,647,698 27,744
2023-06-30 $34,627,944 98,400
2023-06-30 $39,202,774 111,400
2023-06-30 $39,765 113
2023-03-31 $48,615,301 154,300
2023-03-31 $39,352,243 124,900
2023-03-31 $26,404,756 83,806
2022-12-31 $54,666,054 189,300
2022-12-31 $58,798,784 203,611
2022-12-31 $57,496,098 199,100
2022-09-30 $65,088,592 224,800
2022-09-30 $92,392,214 319,100
2022-09-30 $3,985,517 13,765
2022-06-30 $118,661,769 421,100
2022-06-30 $81,662,742 289,800
2022-03-31 $70,983,840 272,000
2022-03-31 $121,351,050 465,000
2022-03-31 $11,118,626 42,605

Report a Problem

Category
Description
Email (optional, for follow-up)